The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).

@article{Pereira2002ThePO,
  title={The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).},
  author={Arlene S Pereira and Laura M. Smeaton and John G. Gerber and Edward P. Acosta and Sally Snyder and Susan A. Fiscus and Richard R. Tidwell and Roy M. Gulick and Robert Murphy and Joseph J Eron},
  journal={The Journal of infectious diseases},
  year={2002},
  volume={186 2},
  pages={198-204}
}
The AIDS Clinical Trials Group Study 850 (ACTG 850) evaluated the penetration of zidovudine (ZDV), lamivudine (3TC), and amprenavir (APV), given alone and in combination with the 2 nucleoside analogues, into the male genital tract, because these factors may affect human immunodeficiency virus (HIV) type 1 suppression and transmission. Nineteen men receiving APV monotherapy and 12 men receiving triple therapy donated blood plasma (BP) and seminal plasma (SP) during therapy. Paired SP and BP were… CONTINUE READING